hrcak mascot   Srce   HID

Pregledni rad

FOLLOW-UP OF PATIENTS WITH CLASSICAL HODGIN LYMPHOMA AFTER TREATMENT – NOVEL EVIDENCE AND DILEMMAS. LITERATURE REVIEW

Vibor Milunović
Karla Mišura Jakobac
Ana Planinc-Peraica
Slobodanka Ostojić Kolonić

Puni tekst: hrvatski, pdf (883 KB) str. 0-0 preuzimanja: 174* citiraj
APA 6th Edition
Milunović, V., Mišura Jakobac, K., Planinc-Peraica, A. i Ostojić Kolonić, S. (2016). PRAĆENJE BOLESNIKA S KLASIČNIM HODGKINOVIM LIMFOMOM NAKON LIJEČENJA – SUVREMENA SAZNANJA I NEDOUMICE. PREGLED LITERATURE. Liječnički vjesnik, 138 (1-2), 0-0. Preuzeto s https://hrcak.srce.hr/172829
MLA 8th Edition
Milunović, Vibor, et al. "PRAĆENJE BOLESNIKA S KLASIČNIM HODGKINOVIM LIMFOMOM NAKON LIJEČENJA – SUVREMENA SAZNANJA I NEDOUMICE. PREGLED LITERATURE." Liječnički vjesnik, vol. 138, br. 1-2, 2016, str. 0-0. https://hrcak.srce.hr/172829. Citirano 19.10.2019.
Chicago 17th Edition
Milunović, Vibor, Karla Mišura Jakobac, Ana Planinc-Peraica i Slobodanka Ostojić Kolonić. "PRAĆENJE BOLESNIKA S KLASIČNIM HODGKINOVIM LIMFOMOM NAKON LIJEČENJA – SUVREMENA SAZNANJA I NEDOUMICE. PREGLED LITERATURE." Liječnički vjesnik 138, br. 1-2 (2016): 0-0. https://hrcak.srce.hr/172829
Harvard
Milunović, V., et al. (2016). 'PRAĆENJE BOLESNIKA S KLASIČNIM HODGKINOVIM LIMFOMOM NAKON LIJEČENJA – SUVREMENA SAZNANJA I NEDOUMICE. PREGLED LITERATURE', Liječnički vjesnik, 138(1-2), str. 0-0. Preuzeto s: https://hrcak.srce.hr/172829 (Datum pristupa: 19.10.2019.)
Vancouver
Milunović V, Mišura Jakobac K, Planinc-Peraica A, Ostojić Kolonić S. PRAĆENJE BOLESNIKA S KLASIČNIM HODGKINOVIM LIMFOMOM NAKON LIJEČENJA – SUVREMENA SAZNANJA I NEDOUMICE. PREGLED LITERATURE. Liječnički vjesnik [Internet]. 2016 [pristupljeno 19.10.2019.];138(1-2):0-0. Dostupno na: https://hrcak.srce.hr/172829
IEEE
V. Milunović, K. Mišura Jakobac, A. Planinc-Peraica i S. Ostojić Kolonić, "PRAĆENJE BOLESNIKA S KLASIČNIM HODGKINOVIM LIMFOMOM NAKON LIJEČENJA – SUVREMENA SAZNANJA I NEDOUMICE. PREGLED LITERATURE", Liječnički vjesnik, vol.138, br. 1-2, str. 0-0, 2016. [Online]. Dostupno na: https://hrcak.srce.hr/172829. [Citirano: 19.10.2019.]

Sažetak
In this review we present current evidence for the follow-up of patients treated for classical Hodgkin lymphoma (HL). Nowadays introduction of novel therapies enabled successful treatment in most patients with classical HL in first remission with 5-year overall survival rate estimation of 80%. We have performed extensive literature search on the ­methodological approach to detection of relapse. Evidence regarding imaging clinical methods in detecting relapse on ­serial computed tomography and/or positron emission tomography scans is scarce. These imaging modalities are associated with considerable economic cost, unnecessary exposure to radiation and patients’ stress. Furthermore, the detection of ­asymptomatic relapse does not seem to be associated with improved outcome in this patient group. Available data on this subject indicate that standard imaging methods, such as ultrasound, and judicious clinical examination in detecting of ­relapse should be the basis of HL patient follow-up. Late toxicity due to various modalities of treatment represents serious morbidity in HL. They vary from secondary solid cancers and hematologic neoplasms, associated with poor outcome, to benign disorders (fertility issues, thyroid dysfunction, cardiovascular and lung disorders). Current data on the incidence, prevalence and etiological factors do not yet provide evidence on appropriate screening methods. Most recommendations in various guidelines are associated with low level of evidence (grade IV). We, therefore, propose individually-tailored screening methods for each patient based on the modality of treatment received.

Ključne riječi
Hodgkin disease – diagnosis, pathology, therapy; Antineoplastic combined chemotherapy protocols – adverse effects, therapeutic use; Neoplasm recurrence, local – diagnosis; Neoplasms, second primary – pathology; Survival rate; Population surveillance – methods; Tomography, X-ray computed; Positron-emission tomography; Heart diseases – etiology; Lung diseases – chemically induced; Bleomycin – adverse effects

Hrčak ID: 172829

URI
https://hrcak.srce.hr/172829

[hrvatski]

Posjeta: 255 *